

CITATION REPORT

List of articles citing

First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis

DOI: 10.1111/bcp.13185

British Journal of Clinical Pharmacology, 2017, 83, 991-1001.

Source: <https://exaly.com/paper-pdf/67659994/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
92	Update on interleukin-17: a role in the pathogenesis of inflammatory arthritis and implication for clinical practice. <i>RMD Open</i> , 2017 , 3, e000284	5.9	59
91	Update on IL-17 Inhibitors for Psoriasis. <i>Current Dermatology Reports</i> , 2017 , 6, 121-128	1.5	
90	Developments with experimental and investigational drugs for axial spondyloarthritis. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 833-842	5.9	1
89	Novel Biologic Agents Targeting Interleukin-23 and Interleukin-17 for Moderate-to-Severe Psoriasis. <i>Clinical Drug Investigation</i> , 2017 , 37, 891-899	3.2	14
88	The role of IL-23 and the IL-23/T 17 immune axis in the pathogenesis and treatment of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 1616-1626	4.6	129
87	First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 991-1001	3.8	74
86	Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2017 , 9, 277-294	3.8	70
85	Emerging drugs for the treatment of axial spondyloarthritis. <i>Expert Opinion on Emerging Drugs</i> , 2018 , 23, 83-96	3.7	9
84	Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, 277-286.e10	4.5	105
83	Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 1111-1119	4.6	47
82	Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 523-532	2.4	123
81	Interleukin-17 Inhibition for the Treatment of Inflammatory Skin Disease. 2018 , 133-144		
80	Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 175-187	2.4	195
79	Unmet Needs in the Field of Psoriasis: Pathogenesis and Treatment. <i>Clinical Reviews in Allergy and Immunology</i> , 2018 , 55, 295-311	12.3	40
78	Emerging treatment options for spondyloarthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018 , 32, 472-484	5.3	10
77	Bimekizumab for the treatment of psoriatic disease. <i>Expert Opinion on Biological Therapy</i> , 2018 , 18, 1193-1197	5.1	11
76	Beyond the TNF-Inhibitors: New and Emerging Targeted Therapies for Patients with Axial Spondyloarthritis and their Relation to Pathophysiology. <i>Drugs</i> , 2018 , 78, 1397-1418	12.1	10

75	The pathogenesis of psoriatic arthritis. <i>Lancet, The</i> , 2018 , 391, 2273-2284	4.0	182
74	IL-17-Blockade in der Psoriasis-Therapie. <i>Karger Kompass Dermatologie</i> , 2018 , 6, 69-78	0	
73	New Pathways and Therapeutic Targets in Autoimmune Myasthenia Gravis. <i>Journal of Neuromuscular Diseases</i> , 2018 , 5, 265-277	5	25
72	The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond. <i>Frontiers in Immunology</i> , 2018 , 9, 1682	8.4	184
71	Tildrakizumab for the treatment of psoriasis. <i>Immunotherapy</i> , 2018 , 10, 1105-1122	3.8	6
70	The use of biomarkers as a tool for novel psoriatic disease drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2018 , 13, 875-887	6.2	2
69	Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis. <i>Frontiers in Pharmacology</i> , 2019 , 10, 872	5.6	43
68	Bedside to bench: defining the immunopathogenesis of psoriatic arthritis. <i>Nature Reviews Rheumatology</i> , 2019 , 15, 645-656	8.1	20
67	Systematic review of immunomodulatory therapies for hidradenitis suppurativa. <i>Biologics: Targets and Therapy</i> , 2019 , 13, 53-78	4.4	24
66	Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential. <i>Psoriasis: Targets and Therapy</i> , 2019 , 9, 29-35	2.4	5
65	Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis. <i>BioDrugs</i> , 2019 , 33, 391-399	7.9	20
64	Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1033-1040	2.4	21
63	Biologic Treatment for Hidradenitis Suppurativa. <i>American Journal of Clinical Dermatology</i> , 2019 , 20, 625-638	7.1	12
62	Posterior Uveitis. <i>Essentials in Ophthalmology</i> , 2019 ,	0.2	
61	IL-17 inhibition in axial spondyloarthritis: current and future perspectives. <i>Expert Opinion on Biological Therapy</i> , 2019 , 19, 631-641	5.4	12
60	Noninfectious Uveitis: Emerging Therapies. <i>Essentials in Ophthalmology</i> , 2019 , 209-225	0.2	
59	Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019 , 23, 50-74	1.6	58
58	Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. <i>The Cochrane Library</i> , 2020 , 1, CD011535	5.2	46

57	mTOR Blockade by Rapamycin in Spondyloarthritis: Impact on Inflammation and New Bone Formation and. <i>Frontiers in Immunology</i> , 2019 , 10, 2344	8.4	8
56	Updated therapies for the management of Psoriatic Arthritis. <i>Clinical Immunology</i> , 2020 , 220, 108536	9	6
55	Synergistic Interaction Between High Bioactive IL-17A and Joint Destruction for the Occurrence of Cardiovascular Events in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2020 , 11, 1998	8.4	3
54	Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F. <i>Frontiers in Immunology</i> , 2020 , 11, 1894	8.4	30
53	The role of Th17 cells in psoriasis. <i>Immunologic Research</i> , 2020 , 68, 296-309	4.3	17
52	Interleukin 17A and IL-17F Expression and Functional Responses in Rheumatoid Arthritis and Peripheral Spondyloarthritis. <i>Journal of Rheumatology</i> , 2020 , 47, 1606-1613	4.1	5
51	Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1367-1374	4.5	28
50	Brodalumab in the treatment of chronic plaque psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 1175-1186	5.4	4
49	IL-15 and IL-23 synergize to trigger Th17 response by CLA T cells in psoriasis. <i>Experimental Dermatology</i> , 2020 , 29, 630-638	4	4
48	Hidradenitis Suppurativa: Current Understanding of Pathogenic Mechanisms and Suggestion for Treatment Algorithm. <i>Frontiers in Medicine</i> , 2020 , 7, 68	4.9	14
47	Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. <i>Lancet, The</i> , 2020 , 395, 427-440	4.0	65
46	Inhibition of interleukins 17A and 17F in psoriatic arthritis. <i>Lancet, The</i> , 2020 , 395, 395-396	4.0	8
45	Selective targeting of PI3K β suppresses human IL-17-producing T cells and innate-like lymphocytes and may be therapeutic for IL-17-mediated diseases. <i>Journal of Autoimmunity</i> , 2020 , 111, 102435	15.5	10
44	Bimekizumab. <i>Current Dermatology Reports</i> , 2020 , 9, 36-42	1.5	2
43	Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 595-604	2.4	46
42	New developments in ankylosing spondylitis-status in 2021.. <i>Rheumatology</i> , 2021 , 60, vi29-vi37	3.9	0
41	Dual inhibition of IL-17A and IL-17F in psoriatic disease. <i>Therapeutic Advances in Chronic Disease</i> , 2021 , 12, 20406223211037846	4.9	4
40	The role of ixekizumab in non-radiographic axial spondyloarthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021 , 13, 1759720X20986734	3.8	3

39	Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. <i>Lancet, The</i> , 2021 , 397, 487-498	4.0	51
38	Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. <i>Lancet, The</i> , 2021 , 397, 475-486	4.0	44
37	An Overview of Bimekizumab for the Treatment of Psoriatic Arthritis: The Evidence so Far. <i>Drug Design, Development and Therapy</i> , 2021 , 15, 1045-1053	4.4	4
36	Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. <i>The Cochrane Library</i> , 2021 , 4, CD011535	5.2	11
35	Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	6
34	From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	0
33	Promising Treatment Options for Axial Spondyloarthritis: An Overview of Experimental Pharmacological Agents. <i>Journal of Experimental Pharmacology</i> , 2021 , 13, 627-635	3	1
32	Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa. <i>Drugs</i> , 2021 , 81, 1397-1410	12.1	2
31	Bimekizumab versus Adalimumab in Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2021 , 385, 130-140	11.2	28
30	Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis. <i>Expert Review of Clinical Immunology</i> , 2021 , 17, 1073-1081	5.1	2
29	Gastroenterological safety of IL-17 inhibitors: a systematic literature review. <i>Expert Opinion on Drug Safety</i> , 2021 , 1-17	4.1	2
28	Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial. <i>JAMA Dermatology</i> , 2021 , 157, 1279-1288	5.1	9
27	Generation and characterization of a humanized anti-IL-17A rabbit monoclonal antibody. <i>Protein Expression and Purification</i> , 2021 , 187, 105950	2	
26	Effect of interleukin-6, -17, -21, -22, and -23 and STAT3 on signal transduction pathways and their inhibition in autoimmune arthritis. <i>Immunologic Research</i> , 2021 , 69, 26-42	4.3	4
25	Emerging Pathophysiological Targets of Psoriasis for Future Therapeutic Strategies. <i>Infectious Disorders - Drug Targets</i> , 2020 , 20, 409-422	1.1	2
24	Treatment of psoriasis: janus kinases inhibitors and biologics for the interleukin-23/Th17 axis. <i>Minerva Medica</i> , 2020 , 111, 254-265	2.2	3
23	Bimekizumab for the Treatment of Psoriasis. <i>Drugs</i> , 2021 , 81, 1751-1762	12.1	5
22	Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis: Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Transcriptomics from a Phase 2a Randomized, Multicenter Double-Blinded Study. <i>British Journal of Dermatology</i> , 2021 ,	4	2

21	Actualizaci3n en terapia biol3gica para psoriasis y artritis psori3tica (parte I): mol3culas pequeas, inhibidores de JAK y agentes biol3gicos (inhibidores IL-17). 2020 , 2, 113-125		
20	Secukinumab for the Treatment of Inflammatory Skin and Joint Disease. 2021 , 243-251		
19	Research Pipeline II: Upcoming Biologic Therapies. 2021 , 303-310		
18	Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. <i>Italian Journal of Dermatology and Venereology</i> , 2021 , 156,	1.2	2
17	Image_1.tif. 2020 ,		
16	Image_2.tif. 2020 ,		
15	Image_3.tif. 2020 ,		
14	Data_Sheet_1.pdf. 2020 ,		
13	DataSheet_1.docx. 2019 ,		
12	Annoying Psoriasis and Atopic Dermatitis: A Narrative Review.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	1
11	Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. <i>The Cochrane Library</i> , 2022 , 2022,	5.2	2
10	Inflammatory Bowel Disease: A Review of Pre-Clinical Murine Models of Human Disease. 2022 , 23, 9344		1
9	Transenteric delivery of antibodies via an orally ingestible robotic pill yields high bioavailability comparable to parenteral administration in awake canines. 2,		
8	Anti-drug antibodies of IL-17 inhibitors for psoriasis: a systematic review. 1-12		
7	Review of bimekizumab in the treatment of psoriasis.		0
6	A Review of the Safety of Interleukin-17A Inhibitor Secukinumab. 2022 , 15, 1365		0
5	Efficacy, Safety and Pharmacokinetics of IL-17 Monoclonal Antibody Injection (AK111) in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blinded, Placebo-Controlled Phase Ib Multidose Escalation Clinical Study.		0
4	Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study.		0

- 3 Adverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping review. 14, ○
- 2 Efficacy and safety of bimekizumab for the treatment of psoriasis: a systematic review and meta-analysis of randomized clinical trials. **2023**, 34, ○
- 1 Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials. **2023**, 14, 204062232311631 ○